Cell substrates: Where do we stand after 50 years of discussion?

Developments in Biologicals

Volumn 123, Issue , 2006, Pages 11-21

  Petricciani, J ^a  

^a CancerVax Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; DNA VACCINE; VACCINE; VIRUS VACCINE;

ANIMAL; BIOSYNTHESIS; CONFERENCE PAPER; CULTURE MEDIUM; CULTURE TECHNIQUE; HELA CELL; HUMAN; SYNTHESIS;

ANIMALS; BACTERIAL VACCINES; CELL CULTURE TECHNIQUES; CULTURE MEDIA; HELA CELLS; HUMANS; VACCINES; VACCINES, DNA; VIRAL VACCINES;

EID: 33644626067     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (29)

1. Hilleman MR: Cells, vaccines, and the pursuit of precedent. NCI Monogr 1968; 29: 463-468.
2. NCI Monogr 1968; 29.
3. Petricciani JC, Hopps HE, Chapple PJ (eds): Cell Substrates. New York, Plenum, 1979.
4. In vitro cellular and developmental biology. Monograph No.6: Abnormal Cells, New Products, and Risk, in Hopps HE, Petricciani JC (eds): Tissue Culture Association, Gaithersberg, MD, 1985.
5. Report of the meting of the study group on biologicals (1987). WHO Technical Report Series, No. 747.
6. Requirements for cell substrates used for production of biologicals (1996). WHO Technical Report Series 1998, No. 878, 19-56.
7. Brown F, Lewis AM, Peden K, Krause P (eds): Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development. Dev Biol. Basel, Karger, 2001, vol 106.
8. Krontiris TG, Cooper GM: Transforming activity of human tumor DNAS. Proc Nat Acad Sci (USA) 1981; 78: 1181-1184.
9. Shih C et al: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261-264.
10. Shih C et al: Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Nat Acad Sci (USA) 1979; 76: 5714-5718.
11. Dortant PM, Claassen JTM, van Krey CF, van Steenis V, Wester PW: Risk assessment on the carcinogenic potential of hybridoma cell DNA: implications for residual contaminating cellular DNA in biological products. Biologicals 1997; 25: 381-390.
12. Levinson AD, Svedersky LP, Palladino MA Jr: Tumorigenic potential of DNA derived from mammalian cell lines, in Hopps HE, Petricciani JC (eds): In vitro cellular and development biology. Monograph No. 6: Abnormal Cells, New Products and Risk. Tissue Culture Association, Gaithersburg, MD, 1985, pp 168-169.
13. Wierenga DE, Cogan J, Petricciani JC: Administration of tumor cell chromatin to immunosuppressed and nonimmunosuppressed nonhuman primates. Biologicals 1995; 23: 221-224.
14. Hilleman MR: Cell line saga - an argument in favor of production of biologies in cancer cells. Adv Exp Biol Med 1978; 118: 47-58.
15. Moore AE: Evidence of oncogenic properties of heteroploid cell lines - Discussion. NCI Monograph 1968; 29: 291-294.
16. Brunschwig A et al: Host resistance to cancer - clinical experiments by homotransplantants, autotransplants and admixture of autologous leucocytes. Ann Surg 1965; 162: 416-425.
17. Southam CM, Moore AE, Rhoads CP: Homotransplantation of human cell lines. Science 1957; 125: 158-160.
18. Greenwald P et al: Morbidity and mortality among recipients of blood from preleukemic and prelymphomatous donors. Cancer 1976; 38: 324-382.
19. Duxbury M, Jezuit M, Letwin B, Wright J: DNA in plasma of human blood for transfusion. Biologicals 1995; 23: 229-231.
20. Corixa Corp. Press release, 15 February 2001.
21. http://www.cancervax.com/vaccine/immune_data.htm#ongoing.
22. Onyvax Ltd. Press release, 17 June 2004.
23. Petricciani JC, Krichstein RL, Hines JE, Wallace RE, Marin DP: Tumorigenicity assays in nonhuman primates treated with antithymocyte globuline. J Natl Cancer Inst 1973; 51: 191-196.
24. Petricciani JC, Krichstein RL, Wallace RE, Marin DP: Assays for cell tumorigenicity in subhuman primates treated with antilymphocte globuline. J Natl Cancer Inst 1972; 48: 705-173.
25. Chang KCE et al: Size distributions of maternal and fetal DNA in Maternal. Plasma Clin Chem 2004; 50: 88-92.
26. Petricciani JP, Regan PJ: Risk of neoplastic transformation from cellular DNA: Calculations using the oncogene model, in Petricciani JC, Hennessen W (eds): Cells-Products-Safety. Dev Biol Stand. Basel, Karger, 1987, vol 68, pp 43-49.
27. Temin H: Overview of biological effects of addition of DNA molecules to cells. J Med Virol 1990; 31: 13-17.
28. Kurth R: Risk potential of the chromosomal insertion of foreign DNA. Ann NY Acad Sci 1995; 772: 140-151.
29. Krause PR, Lewis AM Jr: Safety of viral DNA in biological products. Biologicals 1998; 26: 317-320.